Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical ...

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

The Union government has informed the Bombay High Court that plastic flowers are not included in the list of banned ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Purchase orders for autocomposite improvement program, patent application filings and additional certifications push the ...

The air quality index measures PM2.5, less than 2.5 microns particles, to determine the intensity of air pollution in cities.

Through materials science, we can tailor existing substances or engineer completely novel materials to generate new and ...

Researchers from the University of Glasgow, RMIT University, and Princeton University created a new diamond transistor for ...

A company that emerged from the marine engineering sector holds the secret to the ultra-luxury brand’s remarkable material ...

Chinese researchers are tackling dendrite formation in zinc-ion batteries with the development of an anisotropic and ...

Sailing has been a mainstay of human history for millennia, so it's no surprise that scientists would apply it to traveling ...

The idea of traveling through interstellar space using spacecraft propelled by ultrathin sails may sound like the stuff of sci-fi novels. But in fact, a program started in 2016 by Stephen Hawking and ...